Drug Trial Radar · NCT02737501
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Last checked: Nov 19, 2026Latest source record: Aug 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
May 26, 2016
Primary completion
Jul 28, 2020
Study completion Jan 29, 2021
Sponsor
- Lead sponsor
- Ariad PharmaceuticalsTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS).
Conditions
- Non-small Cell Lung Cancer
- Lung Cancer
- Advanced Malignancies
- Carcinoma
Interventions
BrigatinibDrug
Brigatinib tablets
CrizotinibDrug
Crizotinib tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to end of study (Up to 56 months)
Locations
91 sites in 19 countries. Site status is shown where the registry gives one.
USOR - Arizona Oncology Associates - Sedona
Sedona, Arizona
Kaiser Permanente Bellflower Medical Offices
Bellflower, California
University of Colorado Cancer Center
Aurora, Colorado
Rocky Mountain Cancer Centers - Boulder
Boulder, Colorado
Sylvester Comprehensive Cancer Center
Deerfield Beach, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
West Michigan Cancer Center
Kalamazoo, Michigan
Minnesota Oncology
Coon Rapids, Minnesota
Montefiore Medical Center
The Bronx, New York
Oncology Hematology Care - Blue Ash
Cincinnati, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia
Saint George Hospital
Kogarah, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Monash Medical Centre
Bentleigh East, Victoria, Australia
Saint Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Otto-Wagner-Spital Baumgartner Hohe
Vienna, Austria
Universitatsklinium St. Polten
Sankt Pölten, Lower Austria, Austria
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Odense University Hospital
Odense C, Denmark
Hopital Albert Michallon
Grenoble, Auvergne-Rhône-Alpes, France
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
Centre de Lutte Contre le Cancer Francois Baclesse
Caen, Basse-normandie, France
Hopital Charles Nicolle
Rouen, Haute-normandie, France
Centre Hospitalier Intercommunal de Creteil
Créteil, Île-de-France Region, France
Hopital Tenon
Paris, Île-de-France Region, France
Centre Hospitalier Universitaire Hopital Nord
Marseille, Provence-Alpes-Côte d'Azur Region, France
Evangelische Lungenklinik Berlin
Berlin, Germany
Studiengesellschaft Haemato-Onkologie Hamburg Prof. Laack und Partner
Hamburg, Germany
Universitatsklinik Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, Germany
Pius Hospital Oldenburg
Oldenburg, Lower Saxony, Germany
Kliniken der Stadt Koeln gGmbH - Krankenhaus Merheim
Cologne, North Rhine-Westphalia, Germany
Queen Mary Hospital
Hong Kong, Hong Kong
Queen Elizabeth Hospital
Kowloon, Hong Kong
Tuen Mun Hospital
Tuenmen, New Territories, Hong Kong
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Italy
Istituto Oncologico di Bari Giovanni Paolo II
Bari, Italy
Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi
Bologna, Italy
Istituto Scientifico Universitario San Raffaele
Milan, Italy
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.